Last reviewed · How we verify
Sublingual buprenorphine with naloxone
At a glance
| Generic name | Sublingual buprenorphine with naloxone |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bundled Intervention - Phase 2 (PHASE4)
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation (PHASE4)
- A Study of Brenipatide in Participants With Opioid Use Disorder (PHASE2)
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Buprenorphine for Individuals in Jail (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |